ClinicalTrials.gg
Not yet recruitingNCT07444086Updated Mar 2, 2026

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

A Phase 3 interventional study of QLC7401 and Placebo in Primary Hypercholesterolemia or Mixed Hyperlipidemia, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.

02

Conditions studied

  • Primary Hypercholesterolemia or Mixed Hyperlipidemia
03

In context

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

This study's planned enrollment of 510 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years.
  • Fasting low density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and \<4.9 mmol/L at screening.
  • Atherosclerotic cardiovascular disease (ASCVD) risk stratification as low or intermediate risk per Chinese guidelines.
  • Not currently on lipid-lowering therapy.
  • estimated (eGFR) >30 mL/min/1.73 m².
  • Willing to provide .

Exclusion criteria

Exclusion Criteria:

  • History of AAtherosclerotic cardiovascular disease (ASCVD)(e.g., myocardial infarction, stroke).
  • Familial hypercholesterolemia.
  • Uncontrolled hypertension (Systolic Blood Pressure ≥160 mmHg or (Diastolic Blood Pressure ≥100 mmHg).
  • Poorly controlled type 2 diabetes ( A1c >8.0%).
  • Use of prohibited lipid-lowering drugs within specified .
  • Significant liver or kidney disease.
  • Pregnancy or lactation.
  • Other conditions deemed unsuitable by investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    QLC7401

    Drug: QLC7401

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

  • QLC7401 Injection

  • DrugPlacebo

    Placebo matching QLC7401 in appearance and administration.

06

What researchers measure

Primary outcomes

  1. Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) from Baseline

    Time frame: From baseline to Day 330

Secondary outcomes

  1. Time-adjusted Percent Change in Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Day 90 to Day 360

  2. Change in concentration of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) from Baseline

    Time frame: From baseline to Day 360

  3. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From baseline to Day 360

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Oct 2027, 19 months later.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's planned 19 months is below that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 2, 2026
StartEst.
Mar 5, 2026
Primary completionEst.
Oct 7, 2027
CompletionEst.
Feb 28, 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444086
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 5, 2026 (estimated)
Primary completion
Oct 7, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Yue Li, PhD
Contact
hydy_liyue@163.com
8613945057313

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC7401

Start the discussion